Company intelligence / Profile preview
iNFixion Bioscience
San Diego, California, United Statesinfixionbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
iNFixion’s lead program uses advanced gene regulation techniques to boost neurofibromin production from the healthy copy of the NF1 gene. This approach has shown promising preclinical results in vitro using antisense oligonucleotides. The company’s strategy targets the root cause of NF1 by correcting protein haploinsufficiency rather than only treating symptoms[2][6].
- Therapeutic areas
- Rare Diseases
- Modalities
- Antisense oligonucleotideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Murdoch Children’s Research Institute (potential collaboration identified at Global NF Conference)Abterra Bio/Alicanto® technology for antibody developmentJLABS incubator supportNational Institute of Neurological Disorders and Stroke funding/grants
Beyond the preview
Go deeper on iNFixion Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNFixion Bioscience.